GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE
Post-LOEguaifenesin, pseudoephedrine hydrochloride
ANDAORALTABLET, EXTENDED RELEASE
Approved
Feb 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 18h ago
Mechanism of Action
Pharmacologic Class:
Expectorant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions
Started Dec 2014
80 enrolled
Healthy
Company
Worked on GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.